Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 20;18(1):63.
doi: 10.5334/gh.1275. eCollection 2023.

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy

Marianna Fontana  1 , Aldostefano Porcari  1   2   3 , Philip N Hawkins  1
Affiliations
Editorial

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy

Marianna Fontana et al. Glob Heart. .

Abstract

Transthyretin cardiac amyloidosis (ATTR-CA) has been traditionally considered a rare and inexorably fatal condition. ATTR-CA now is an increasingly recognised cause of heart failure and mortality worldwide with effective pharmacological treatments. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have transformed the diagnosis of ATTR-CA, which is now possible without recourse to endomyocardial biopsy in around 70% of cases. Many patients are now diagnosed at an earlier stage. Echocardiography and cardiac magnetic resonance have enabled identification of patients with possible ATTR-CA and more accurate prognostic stratification. Therapies able to slow or halt ATTR-CA progression and increase survival are now available and there is also evidence that patients may benefit from specific conventional heart failure medications. A wide horizon of possibilities is unfolding and awaits discovery.

Keywords: Cardiac Amyloidosis; Diagnosis; Prognosis; Transthyretin; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

Comment on

  • World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
    Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ. Brito D, et al. Glob Heart. 2023 Oct 26;18(1):59. doi: 10.5334/gh.1262. eCollection 2023. Glob Heart. 2023. PMID: 37901600 Free PMC article. Review.

References

    1. Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. European Journal Internal Medicine. 2020; 82: 7–15. DOI: 10.1016/j.ejim.2020.09.025 - DOI - PMC - PubMed
    1. Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, et al. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. Journal American College Cardiology. 2022; 79: 1288–1303. DOI: 10.1016/j.jacc.2022.01.036 - DOI - PubMed
    1. Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. European Journal Heart Failure. 2023; 25: 515–524. DOI: 10.1002/ejhf.2776 - DOI - PubMed
    1. Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis. European Journal Heart Failure. 2022; 24: 2355–2363. DOI: 10.1002/ejhf.2646 - DOI - PMC - PubMed
    1. Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal Heart Failure. 2022; 24: 1700–1712. DOI: 10.1002/ejhf.2606 - DOI - PMC - PubMed